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Aim: To determine the efficacy of ultrasound (US) examinations and the added value 
of CA-125 measurement in the diagnosis of peri- and postmenopausal ovarian cysts. 
Materials and Methods: Imaging properties of peri- (PEM) and postmenopausal 
(POM) ovarian cysts were examined preoperatively. According to US findings two 
groups were made: (1) simple cysts: unilocular, anechoic cysts without 
papillarization, (2) complex cysts: cystic structures with different parameters. 
Imaging characteristics, size were matched with histology and CA125 levels. 
Results: 379 cystic structures (PEM: N=195, average age: 45.6yrs; range: 40-54yrs, 
POM: N=184, average age 61.2yrs; range: 41-88yrs) were analysed preoperatively. In 
the PEM group 75 simple (Ø<5cm N=32, Ø≥5cm N=43) and 122 complex cysts 
(Ø<5cm N=29, Ø≥5cm, N=93), while in the POM group 49 simple (Ø<5cm N=9, 
Ø≥5cm N=40) and 135 complex cysts (Ø<5cm N=15, Ø≥5cm N=120) were found. In 
the PEM group malignancy was detected in complex cysts larger than 5cm (N=16, 
17.58%). In the POM group we found malignancy in 40 cases, three of them smaller 
than 5cm. Majority of cysts were functional (54.36 %) in the PEM group. In the POM 
group serous cysts were the most frequent (38.04%), followed by malignant 
(21.74%) and mucinous cysts (13.04%). CA125 were elevated in 66 of 217 cases 
(30.41%), only 23 of these were malignant (NPV: 0.95, PPV: 0.35). 
Discussion: Functional cysts are frequently found among perimenopausal ovarian 
cysts, and we detected malignancy only among complex cysts larger than 5cms. 
However, complex cyst of any size carry significant risk of malignancy in the 
postmenopause, thus surgery is recommended. Simple cysts can be followed by 
serial scan in both groups. CA-125 did not give added value to the detection of 
malignancy. 
Introduction 
It is well known fact that the number of ovarian cystic structures in the peri and 
postmenopausal age is increased. The detection of these cysts can be achieved by 
bimanual examination, serum tumour markers and transvaginal ultrasound 
examinations, as well. Functional and malignant cysts can be characterized by their 
symptoms at the same time. Moreover the detection of these structures the dignity 
is the second most important thing to determine. In case of ovarian malignancies CA-
125 was recommended to increase the detection rate but it can be used effectively 
together with transvaginal US scans. The aim of this study was to determine the 
efficacy of grayscale ultrasound scans and the additive value of CA-125 in the 
detection of ovarian cystic structures in the peri- and postmenopause. 
Materials 
This study was performed in the Department of Obstetrics and Gynaecology at the 
University of Debrecen, Debrecen, Hungary. Imaging properties of peri- (PEM) and 
postmenopausal (POM) ovarian cysts were examined preoperatively. All patients 
underwent transvaginal ultrasound examinations preoperatively (ATL HDI-3000, 
Bothell, Washington equipped with 5,9MHz transvaginal probe). Patients at least at 
the age of 40 without climacteric symptoms were involved in the PEM group such as 
those who previously underwent hysterectomy under the age of 50 (range: 40-54yrs, 
average: 45.57yrs). The lack of regular menses for more than one year or 
hysterectomy in the anamnesis and the patient is at least 50 were put in the POM 
group (range: 41-88yrs, average: 61,24yrs). Overall 343 patients with 379 cystic 
structures were involved in the study. The US examinations were independent from 
the menstrual cycle and were repeated within three months in 168 cases (44,32%). 
When follow-up was performed only the preoperative US finding was chosen to 
participate. According to US findings two groups were made: (1) simple cysts: 
unilocular, anechoic cysts without papillarization, (2) complex cysts: cystic structures 
with different parameters. Imaging characteristics, size were matched with histology 
and CA125 levels. The cut-off level for CA-125 was 35 kIU/L. According to the size of 
the cysts two subgroups were made within each reproductive group and 5cm was 
chosen for this purpose. Risk factors affecting the formation of cystic structures in 
the ovary were also observed in this study such as parity, previous pelvic surgeries, 
family history of ovarian cancer. 
Results 
In the PEM group 75 simple (Ø<5cm N=32, Ø≥5cm N=43) and 122 complex cysts 
(Ø<5cm N=29, Ø≥5cm, N=93), while in the POM group 49 simple (Ø<5cm N=9, 
Ø≥5cm N=40) and 135 complex cysts (Ø<5cm N=15, Ø≥5cm N=120) were found. In 
the PEM group malignancy was detected in complex cysts larger than 5cm (N=16, 
17.58%). In the POM group we found malignancy in 40 cases, three of them smaller 
than 5cm. Majority of cysts were functional (54.36 %) in the PEM group. In the POM 
group serous cysts were the most frequent (38.04%), followed by malignant 
(21.74%) and mucinous cysts (13.04%). It should be noticed that in the POM group 
we can meet functional cysts in 5.43% of the cases (N=10). Details are shown in 
Table 1. 
The factors affecting the formation of cystic structures in the ovary can be seen in 
Table 2. We found at least one delivery in 84.96% of the cases. 210 cysts caused 
some kind of complaint for the patient (55.41%) the most common was pelvic pain in 
160 cases (42.22%). In 336 cases laparotomy was performed (88.65%). Previous 
interventions affecting the pelvis were found overall in 114 cases (30,08%), majority 
of these were hysterectomy (N=71, 18,73%). Family history for ovarian cancer was 
found in 4 cases (1.06%). 
CA125 evaluation was performed in 217 cases, elevated in 66 cases (30.41%), only 23 
(10.60%) of these were malignant (NPV: 0.95, PPV: 0.35). Results are shown in Table 
3. 
Discussion 
Cystic structures of the ovaries can be found in 11-16% of the cases in 
postmenopause and more frequently in the perimenopause. The risk of malignant 
transformation of benign cysts is still an open question in the literature. It was 
proven in several studies that the risk of malignant transformation is directly 
proportional to the number of EGF receptors in the cystic fluid. In our study we did 
not observe this connection. 
According to the fact that ovarian pathologies depend on the functional state of 
the ovaries the division of the population into peri-and postmenopausal groups are 
necessary. Koonings et al. found 13% risk for malignant transformation in the 
perimenopause, which increases to 45% in the postmenopausal group. This 
transformation is more likely to develop in larger cysts. Modesitt et al advised 10cms 
for cut off level while Osmers et al found 3cms of diameter for the border between 
low risk and high-risk groups. 5cms was recommended by Auslender et al. and 
Reimer et al. and so it was used in this study as well. 
In this study it was shown that perimenopausal cystic structures carry malignancy 
in 4.22% of the cases which correlates with the results of Ekerhovd et al (0.7%) and 
Osmers et al. (0.8%). Echogenicity, wall structure, septation and presence of 
papillarization should be noticed when considering about complexity of a cyst 
because this is compulsory for a correct diagnostic decision. Timmermann et al and 
Ueland et al designed scoring systems based on the volume of cysts and wall 
structures to help these decisions. These systems were not used in this study. 
In the postmenopausal group the risk of malignancy is not irrelevant which fact 
was supported by our result: 40 cysts found out to be malignant (10.55%) of the 
cases, 39 of them proved to have complex morphological findings. Our data 
correlates with the results of Osmers et al (9.6%) and Ekerhovd et al. (10%). 
According to these facts surgical removal of these structures is necessary. Simple 
postmenopausal cysts can carry malignancy in only 0.26% of the cases, their regular 
follow-up is recommended with or without determination of CA-125. CA-125 alone 
has a very low screening sensitivity for stage I. ovarian cancer (60%) and a specificity 
of 99% (Bast et al.). In combination with TVS sensitivity increases up to 85% (Jacobs 
et al.). In this study the detection rate was only 30.41%. It can be elevated in benign 
diseases such as endometriosis, PID, fibroids and Meigs-syndrome. Several studies 
support that it has to be used together with ultrasound scans to improve its 
diagnostic benefit and should not be used alone for the decision of the dignity of 
ovarian cysts. A diagnostic algorithm based on ultrasonography can easily decrease 
the number of surgeries and high hospital costs. 
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